Skip to main content
In stock | Targeted Therapy (Investigational)

Bezuclastinib

Oncology Type Both (Solid & Hematologic)
Drug Class / Mechanism Selective KIT D816V Inhibitor
No Image
Description

Bezuclastinib is classified as a Selective KIT D816V Inhibitor, sourced for use within our Targeted Therapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Investigational)
Oncology Type Both (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3